Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary

András Inotai, Zsolt Abonyi-Tóth, György Rokszin, Z. Vokó

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: There is an increasing social debate on expenditures on the care of patients with malignant diseases, especially in Central Eastern European countries with limited health resources. Objectives: The aim of this research was to estimate the epidemiological and quality measures and resource use indicators in Hungary in four malignant conditions (breast, colorectal, lung, and prostate cancer) from the National Health Insurance Fund (NHIF) database. Methods: Survival and cost analyses were performed on the NHIF database. Patient records containing the International Classification of Diseases (. ICD) codes C50 (breast cancer), C18-C20 (colorectal cancer), C33-C34 (lung cancer), and C61 (prostate cancer) were considered eligible. Inclusion criteria were at least two consecutive ICD codes between 2000 and 2012, with a minimum of 30-day difference, or one ICD code, followed by patient death within 60 days. A total of 428,860 social insurance numbers met inclusion criteria. Results: The number of new cases was 6381 for breast cancer, 8457 for colorectal cancer, 8902 for lung cancer, and 3419 for prostate cancer. The probability of 5-year overall survival from the first diagnosis was 75.2%, 41.3%, 17.1%, and 62.1%, respectively. Median time from first diagnosis to treatment initiation was less than 1 month in all conditions except for lung cancer. The annual cost of treatment was €2585, €3165, €4157, and €2834, respectively. Cost figures were compared with hemophilia as benchmark (€8284). Conclusions: The results indicated that the database of the Hungarian NHIF is suitable for real-world data analysis in the field of oncology and can support long-term evidence-based policymaking.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalValue in Health Regional Issues
Volume7
DOIs
Publication statusPublished - Sep 1 2015

Fingerprint

Hungary
Colorectal Neoplasms
Lung Neoplasms
Prostatic Neoplasms
Breast Neoplasms
National Health Programs
Costs and Cost Analysis
International Classification of Diseases
Databases
Benchmarking
Social Security
Health Resources
Hemophilia A
Survival Analysis
Health Expenditures
Health Care Costs
Patient Care
Breast cancer
Colorectal cancer
Prostate cancer

Keywords

  • Breast cancer
  • Colorectal cancer
  • Cost
  • Evidence-based policymaking
  • Hemophilia
  • Lung cancer
  • Mortality
  • New cases
  • Payer's database
  • Prostate cancer
  • Survival
  • Time to treatment

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Economics, Econometrics and Finance (miscellaneous)

Cite this

Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary. / Inotai, András; Abonyi-Tóth, Zsolt; Rokszin, György; Vokó, Z.

In: Value in Health Regional Issues, Vol. 7, 01.09.2015, p. 1-8.

Research output: Contribution to journalArticle

Inotai, András ; Abonyi-Tóth, Zsolt ; Rokszin, György ; Vokó, Z. / Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary. In: Value in Health Regional Issues. 2015 ; Vol. 7. pp. 1-8.
@article{1e16df7396064835a3e48d16c9883927,
title = "Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary",
abstract = "Background: There is an increasing social debate on expenditures on the care of patients with malignant diseases, especially in Central Eastern European countries with limited health resources. Objectives: The aim of this research was to estimate the epidemiological and quality measures and resource use indicators in Hungary in four malignant conditions (breast, colorectal, lung, and prostate cancer) from the National Health Insurance Fund (NHIF) database. Methods: Survival and cost analyses were performed on the NHIF database. Patient records containing the International Classification of Diseases (. ICD) codes C50 (breast cancer), C18-C20 (colorectal cancer), C33-C34 (lung cancer), and C61 (prostate cancer) were considered eligible. Inclusion criteria were at least two consecutive ICD codes between 2000 and 2012, with a minimum of 30-day difference, or one ICD code, followed by patient death within 60 days. A total of 428,860 social insurance numbers met inclusion criteria. Results: The number of new cases was 6381 for breast cancer, 8457 for colorectal cancer, 8902 for lung cancer, and 3419 for prostate cancer. The probability of 5-year overall survival from the first diagnosis was 75.2{\%}, 41.3{\%}, 17.1{\%}, and 62.1{\%}, respectively. Median time from first diagnosis to treatment initiation was less than 1 month in all conditions except for lung cancer. The annual cost of treatment was €2585, €3165, €4157, and €2834, respectively. Cost figures were compared with hemophilia as benchmark (€8284). Conclusions: The results indicated that the database of the Hungarian NHIF is suitable for real-world data analysis in the field of oncology and can support long-term evidence-based policymaking.",
keywords = "Breast cancer, Colorectal cancer, Cost, Evidence-based policymaking, Hemophilia, Lung cancer, Mortality, New cases, Payer's database, Prostate cancer, Survival, Time to treatment",
author = "Andr{\'a}s Inotai and Zsolt Abonyi-T{\'o}th and Gy{\"o}rgy Rokszin and Z. Vok{\'o}",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.vhri.2015.03.020",
language = "English",
volume = "7",
pages = "1--8",
journal = "Value in Health Regional Issues",
issn = "2212-1099",
publisher = "Elsevier USA",

}

TY - JOUR

T1 - Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary

AU - Inotai, András

AU - Abonyi-Tóth, Zsolt

AU - Rokszin, György

AU - Vokó, Z.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Background: There is an increasing social debate on expenditures on the care of patients with malignant diseases, especially in Central Eastern European countries with limited health resources. Objectives: The aim of this research was to estimate the epidemiological and quality measures and resource use indicators in Hungary in four malignant conditions (breast, colorectal, lung, and prostate cancer) from the National Health Insurance Fund (NHIF) database. Methods: Survival and cost analyses were performed on the NHIF database. Patient records containing the International Classification of Diseases (. ICD) codes C50 (breast cancer), C18-C20 (colorectal cancer), C33-C34 (lung cancer), and C61 (prostate cancer) were considered eligible. Inclusion criteria were at least two consecutive ICD codes between 2000 and 2012, with a minimum of 30-day difference, or one ICD code, followed by patient death within 60 days. A total of 428,860 social insurance numbers met inclusion criteria. Results: The number of new cases was 6381 for breast cancer, 8457 for colorectal cancer, 8902 for lung cancer, and 3419 for prostate cancer. The probability of 5-year overall survival from the first diagnosis was 75.2%, 41.3%, 17.1%, and 62.1%, respectively. Median time from first diagnosis to treatment initiation was less than 1 month in all conditions except for lung cancer. The annual cost of treatment was €2585, €3165, €4157, and €2834, respectively. Cost figures were compared with hemophilia as benchmark (€8284). Conclusions: The results indicated that the database of the Hungarian NHIF is suitable for real-world data analysis in the field of oncology and can support long-term evidence-based policymaking.

AB - Background: There is an increasing social debate on expenditures on the care of patients with malignant diseases, especially in Central Eastern European countries with limited health resources. Objectives: The aim of this research was to estimate the epidemiological and quality measures and resource use indicators in Hungary in four malignant conditions (breast, colorectal, lung, and prostate cancer) from the National Health Insurance Fund (NHIF) database. Methods: Survival and cost analyses were performed on the NHIF database. Patient records containing the International Classification of Diseases (. ICD) codes C50 (breast cancer), C18-C20 (colorectal cancer), C33-C34 (lung cancer), and C61 (prostate cancer) were considered eligible. Inclusion criteria were at least two consecutive ICD codes between 2000 and 2012, with a minimum of 30-day difference, or one ICD code, followed by patient death within 60 days. A total of 428,860 social insurance numbers met inclusion criteria. Results: The number of new cases was 6381 for breast cancer, 8457 for colorectal cancer, 8902 for lung cancer, and 3419 for prostate cancer. The probability of 5-year overall survival from the first diagnosis was 75.2%, 41.3%, 17.1%, and 62.1%, respectively. Median time from first diagnosis to treatment initiation was less than 1 month in all conditions except for lung cancer. The annual cost of treatment was €2585, €3165, €4157, and €2834, respectively. Cost figures were compared with hemophilia as benchmark (€8284). Conclusions: The results indicated that the database of the Hungarian NHIF is suitable for real-world data analysis in the field of oncology and can support long-term evidence-based policymaking.

KW - Breast cancer

KW - Colorectal cancer

KW - Cost

KW - Evidence-based policymaking

KW - Hemophilia

KW - Lung cancer

KW - Mortality

KW - New cases

KW - Payer's database

KW - Prostate cancer

KW - Survival

KW - Time to treatment

UR - http://www.scopus.com/inward/record.url?scp=84928234929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928234929&partnerID=8YFLogxK

U2 - 10.1016/j.vhri.2015.03.020

DO - 10.1016/j.vhri.2015.03.020

M3 - Article

VL - 7

SP - 1

EP - 8

JO - Value in Health Regional Issues

JF - Value in Health Regional Issues

SN - 2212-1099

ER -